A single genetic defect can have a serious impact on a child’s life. For instance, children with Severe Combined Immunodeficiency (SCID) are born without a functioning immune system. Even minor infections can become life-threatening, and without treatment, many do not survive their first year. Such severe conditions are rare, but for families affected, the diagnosis is heartbreaking and marks the start of a difficult and uncertain journey. At Genewity, we are developing pioneering stem cell-based gene therapies that target the root cause of these diseases. Our clinical-stage program (executed by subsidiary Videja) has already demonstrated the potential for one-time, durable treatments. We are advancing a pipeline of therapies aimed at transforming the lives of children with severe unmet medical needs.